Topical immune response modifiers: Adjuvants

Annemarie Uliasz; Mark Lebwohl

doi:10.1007/978-1-84800-165-7_29

Topical immune response modifiers: Adjuvants

Annemarie Uliasz, Mark Lebwohl

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The topical immune response modifier imiquimod is a low molecular weight heterocycline imidazoquinoline amine. Imiquimod stimulates both the innate and the acquired arms of the immune system via induction of T-helper-1 cytokines Imiquimod is Food and Drug Administration approved for the treatment of anogenital warts, but is widely used to treat other warts and molluscum contagiosum. Nonantiviral uses of imiquimod include actinic keratoses and superficial basal cell carcinomas.

Original language	English
Title of host publication	Clinical and Basic Immunodermatology
Publisher	Springer London
Pages	527-537
Number of pages	11
ISBN (Print)	9781848001640
DOIs	https://doi.org/10.1007/978-1-84800-165-7_29
State	Published - 2008

Access to Document

10.1007/978-1-84800-165-7_29

Cite this

@inbook{7baf6fa1ec7d40fcb600957a85a5acd0,

title = "Topical immune response modifiers: Adjuvants",

abstract = "The topical immune response modifier imiquimod is a low molecular weight heterocycline imidazoquinoline amine. Imiquimod stimulates both the innate and the acquired arms of the immune system via induction of T-helper-1 cytokines Imiquimod is Food and Drug Administration approved for the treatment of anogenital warts, but is widely used to treat other warts and molluscum contagiosum. Nonantiviral uses of imiquimod include actinic keratoses and superficial basal cell carcinomas.",

author = "Annemarie Uliasz and Mark Lebwohl",

year = "2008",

doi = "10.1007/978-1-84800-165-7_29",

language = "English",

isbn = "9781848001640",

pages = "527--537",

booktitle = "Clinical and Basic Immunodermatology",

publisher = "Springer London",

address = "United Kingdom",

}

TY - CHAP

T1 - Topical immune response modifiers

T2 - Adjuvants

AU - Uliasz, Annemarie

AU - Lebwohl, Mark

PY - 2008

Y1 - 2008

N2 - The topical immune response modifier imiquimod is a low molecular weight heterocycline imidazoquinoline amine. Imiquimod stimulates both the innate and the acquired arms of the immune system via induction of T-helper-1 cytokines Imiquimod is Food and Drug Administration approved for the treatment of anogenital warts, but is widely used to treat other warts and molluscum contagiosum. Nonantiviral uses of imiquimod include actinic keratoses and superficial basal cell carcinomas.

AB - The topical immune response modifier imiquimod is a low molecular weight heterocycline imidazoquinoline amine. Imiquimod stimulates both the innate and the acquired arms of the immune system via induction of T-helper-1 cytokines Imiquimod is Food and Drug Administration approved for the treatment of anogenital warts, but is widely used to treat other warts and molluscum contagiosum. Nonantiviral uses of imiquimod include actinic keratoses and superficial basal cell carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=84890170449&partnerID=8YFLogxK

U2 - 10.1007/978-1-84800-165-7_29

DO - 10.1007/978-1-84800-165-7_29

M3 - Chapter

AN - SCOPUS:84890170449

SN - 9781848001640

SP - 527

EP - 537

BT - Clinical and Basic Immunodermatology

PB - Springer London

ER -

Topical immune response modifiers: Adjuvants

Abstract

Access to Document

Fingerprint

Cite this